Arcutis Biotherapeutics Inc (OQ:ARQT)
Business Focus: Bio Therapeutic Drugs
|
| INK Ultra Money Free |
| Latest 10 SEC filings (by transaction date) for ARQT within the last 6 months | [?] |
 Amended Filing  Footnote and/or Remark | |
As of 11:59pm ET January 25th, 2021
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
|---|---|---|---|---|---|---|---|
| Jan 21/21 | Jan 19/21 | Moore Matthew Richard | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 80,000 | |
| Jan 21/21 | Jan 19/21 | Moore Matthew Richard | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 80,000 | |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -500 | |
| Jan 21/21 | Jan 19/21 | Smither John W | Indirect Ownership | Common Stock | S - Open market or private sale | -1,250 | $30.00 |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Common Stock | S - Open market or private sale | -500 | $30.00 |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 500 | $1.68 |
| Jan 14/21 | Jan 12/21 | Welgus Howard G. | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -1,222 | |
| Jan 14/21 | Jan 12/21 | Welgus Howard G. | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,222 | $0.580 |
| Jan 7/21 | Jan 5/21 | Watanabe Todd Franklin | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -10,000 | |
| Jan 7/21 | Jan 5/21 | Watanabe Todd Franklin | Direct Ownership | Common Stock | S - Open market or private sale | -10,000 | $28.08 |
| Sign up or login above to see all SEC filings within the past 6 months. | |||||||
| Latest 10 SEC filings (by filing date) for ARQT within the last 6 months | [?] |
| Amended Filing Footnote and/or Remark | |
As of 11:59pm ET January 25th, 2021
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
|---|---|---|---|---|---|---|---|
| Jan 21/21 | Jan 19/21 | Moore Matthew Richard | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 80,000 | |
| Jan 21/21 | Jan 19/21 | Moore Matthew Richard | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 80,000 | |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -500 | |
| Jan 21/21 | Jan 19/21 | Smither John W | Indirect Ownership | Common Stock | S - Open market or private sale | -1,250 | $30.00 |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Common Stock | S - Open market or private sale | -500 | $30.00 |
| Jan 21/21 | Jan 19/21 | Smither John W | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 500 | $1.68 |
| Jan 14/21 | Jan 12/21 | Welgus Howard G. | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -1,222 | |
| Jan 14/21 | Jan 12/21 | Welgus Howard G. | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,222 | $0.580 |
| Jan 7/21 | Jan 5/21 | Watanabe Todd Franklin | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -10,000 | |
| Jan 7/21 | Jan 5/21 | Watanabe Todd Franklin | Direct Ownership | Common Stock | S - Open market or private sale | -10,000 | $28.08 |
| Sign up or login above to see all SEC filings within the past 6 months. | |||||||
| Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors
| Competitors with Recent Insider Filings |
| Cerevel Therapeutics Hold (OQ:CERE) |
| Regeneron Pharmaceuticals (OQ:REGN) |
| PTC Therapeutics (OQ:PTCT) |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2021 INK Research Corp. All rights reserved.
North American company fundamental and Canadian price data sourced from © Thomson Reuters Limited. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent
of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for
any actions taken in reliance on such content. 'Thomson Reuters' and the Thomson Reuters logo are trademarks of
Thomson Reuters and its affiliated companies.
US Quotes Data provided by IEX
North American company fundamental and Canadian price data sourced from © Thomson Reuters Limited. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent
of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for
any actions taken in reliance on such content. 'Thomson Reuters' and the Thomson Reuters logo are trademarks of
Thomson Reuters and its affiliated companies.